Innoviva Q3 2026 earnings

INVA · 2026-11-04 16:25 AMC ET · 8-K on SEC

Revenue grew but net income swung to a loss driven by large equity investment losses.

Headline numbers

MetricActualYoYQoQ8-K location
EPS (GAAP)-$1.03-179.2%-9.7%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Royalty revenue, net$54.7M-8.8%51.5%Durable portfolio
Net product sales$49.4M+4.5%46.6%IST U.S. sales
License and other revenue$2.0M+231.0%1.9%—

Margins and costs

  • Gross margin 79.4% (prior 75.2%, change +4.2 pp)
  • Operating expenses $42.2M (+3.1% YoY)
  • One-offs in the quarter Changes in fair values of equity method investments, net: -$97.6M; Changes in fair values of equity and long-term investments, net: -$41.9M; Income tax benefit (expense): $23.7M
  • Effective tax rate 24.3% (prior-year -10.2%, year-to-date 1.2%)
  • Non-GAAP bridge Adds back changes in fair values of equity method and long-term investments, and income tax benefit/expense to get from GAAP to operating income.

KPIs

MetricActualPrior quarterPrior yearChange
IST U.S. net product sales$43.3M$36.6M$29.8M+45% YoY
Cash and cash equivalents$581.4M$570.4M$397.5M+46.1% YoY
Share repurchases1.2M shares1.2M shares1.2M sharesUnder $125M program

Guidance

MetricGuidePrior guideChange
IST U.S. net product salesAt least $150MAt least $150MNo change

What drove it

  • Revenue story Total revenue decreased 1.6% YoY, driven by a 8.8% decline in royalty revenue, offset by a 4.5% increase in net product sales.
  • EPS story GAAP EPS swung to a loss of -$1.03, driven by a $139.5M swing in equity investment losses and a $31.6M swing in tax benefit.
  • One-off check Equity method investments: -$97.6M; Equity and long-term investments: -$41.9M; Tax benefit: $23.7M.

The good

  • IST U.S. net product sales grew 45% YoY to $43.3M
  • Gross margin expanded 4.2 pp to 79.4%
  • Operating income grew 21.9% YoY to $42.2M

The bad

  • Royalty revenue declined 8.8% YoY to $54.7M
  • Total revenue declined 1.6% YoY to $106.1M
  • Net income swung to a loss of $73.9M

The ugly

  • none

Open questions

  • What caused the 8.8% decline in royalty revenue?
  • What is the expected timing and magnitude of recovery for the equity method investment losses?
  • Why did the equity method investment value drop significantly in Q3 after a gain in Q2?
Full release

Innoviva (INVA) earnings release, November 4, 2026

Innoviva, Inc. (INVA) · Form 8-K, Item 2.02 · Filed · SEC filing

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth

$58.1 million in quarterly revenue from durable royalty portfolio

Returned capital to shareholders through repurchase of 1.2 million shares in Q3 under $125 million buyback program

BURLINGAME, Calif. – Nov 4, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements.

“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales. We are excited about the potential to meaningfully expand the reach of our products and expect operating leverage, supported by sustained fiscal discipline, to strengthen the business’s profitability as revenues grow. Marking another milestone for IST, NUZOLVENCE®, a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea, is now commercially available in the U.S.,” said Pavel Raifeld, Chief Executive Officer of Innoviva.

“Our durable royalty portfolio, coupled with a strong balance sheet and IST’s expanding revenue base, provides a strong foundation for disciplined, value-accretive capital allocation. To that end, we evaluate new opportunities that can broaden our portfolio and further accelerate growth alongside investments in our high-potential strategic healthcare assets. We also continue to execute on our share repurchase program, reflecting our excitement and conviction in Innoviva’s long-term prospects,” concluded

Mr. Raifeld.

Financial Highlights

Business Highlights

- 2 -

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva

Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®

/BREO®

ELLIPTA® and ANORO®

ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA®

(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO®

(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of

Acinetobacter baumannii-calcoaceticus, XERAVA®

(eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA®

(ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and

NUZOLVENCE®

(zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg.

For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Royalty revenue, net (1)54,65759,896166,158181,583
Net product sales49,44447,294142,586113,066
License and other revenue2,01961014,9612,066
Total revenue106,120107,800323,705296,715
Cost of products sold (inclusive of amortization of inventory fair value adjustments)15,03825,64352,99445,075
Amortization of acquired intangible assets6,7006,61819,88019,640
Gross profit84,38275,539250,831232,000
Operating expenses:
Selling, general and administrative37,01527,291104,02481,194
Research and development5,21413,67015,64526,049
Total operating expenses42,22940,961119,669107,243
Income from operations42,15334,578131,162124,757
Changes in fair values of equity method investments, net-97,58530,751-71,76930,284
Changes in fair values of equity and long-term investments, net-41,90431,510-37,482-22,509
Interest and dividend income5,3165,47223,90214,935
Interest expense-5,472-4,015-16,381-13,389
Other expense, net-118-479-499-2,252
Income (loss) before income taxes-97,61097,81728,933131,826
Income tax benefit (expense)23,722-7,909354-24,814
Net income (loss)-73,88889,90829,287107,012
Net income (loss) per share:
Basic-1.031.30.41.65
Diluted-1.031.080.41.35
Shares used to compute net income (loss) per share:
Basic72,06869,05873,20964,901
Diluted72,06884,96473,96984,576

Balance Sheet

September 30, 2026 — (unaudited) (in thousands)

September 30, 2026December 31, 2025
Assets
Cash and cash equivalents581,394550,941
Royalty and product sale receivables102,13093,317
Inventory42,83839,172
Prepaid expense and other current assets37,22528,358
Current portion of ISP Fund investments8,66715,727
Property and equipment, net2,0381,555
Equity method and equity and long-term investments526,791598,223
Capitalized fees45,77056,138
Right-of-use assets10,10010,929
Goodwill17,90517,905
Intangible assets162,276182,156
Other assets79240,744
Total assets1,537,9261,635,165
Liabilities and stockholders’ equity
Other current liabilities44,79543,808
Accrued interest payable2311,618
Deferred revenue5,0044,270
Convertible senior notes, due 2028, net258,822257,731
Deferred tax liabilities, net6,91431,793
Income tax payable, long term19,40657,013
Other long term liabilities65,23666,091
Stockholders’ equity1,137,5181,172,841
Total liabilities and stockholders’ equity1,537,9261,635,165

Cash Flow

Nine Months Ended September 30, — (unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net cash provided by operating activities128,952142,417
Net cash provided by (used in) investing activities-23,68516,860
Net cash provided by (used in) financing activities-74,81412,272
Net change30,453171,549
Cash and cash equivalents at beginning of period550,941304,964
Cash and cash equivalents at end of period581,394476,513

Forward-looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation

Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of

RELVAR®

/BREO®

ELLIPTA®, ANORO®

ELLIPTA®, GIAPREZA®,

XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to

- 3 - shareholders; the development of the LYNX®... (truncated)udies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form

10-K for the year ended December 31, 2025 and Quarterly Reports on Form

10-Q, which are on file with the Securities and Exchange

Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

- 4 -

INNOVIVA, INC.

Condensed Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

- 5 -

INNOVIVA, INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

- 6 -

INNOVIVA, INC.

Cash Flows Summary

(in thousands)

(unaudited)

- 7 -

CONTACTS

Media

Amanda Brown Galgay

Vice President, Communications amanda.galgay@inva.com

Investors

Irwin Tendler

Head of Investor Relations

Executive Director, Corporate

Development investors.relations@inva.com

- 8 -

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.